Novartis Deal Activity — 56 Deals Analyzed, 2024–2026

56 Deals in 27 Months: Novartis Is on a Tear

Novartis executed 56 deals between March 18, 2024 and July 8, 2026, making it one of the most active acquirers and licensors in large-cap pharma during this period. The dominant theme is unmistakable: oncology and next-generation drug conjugate platforms. Of the ten most recent transactions, eight are oncology-linked, and at least four involve antibody-drug conjugate (ADC) or molecular glue modalities at the discovery or preclinical stage. This is not a company plugging near-term revenue gaps. This is a company building a five-to-ten-year oncology weapons cache.

The therapeutic area spread — oncology, immunology, neurology, rare disease, cardiovascular, and gastroenterology — looks broad on paper. In practice, the deal flow is overwhelmingly concentrated in oncology and platform-level mega-deals, with immunology (notably the $160M upfront ANGPTL3 RNA deal) and neurology functioning as secondary pillars rather than primary investment theses.

Novartis's Deal Portfolio

The pattern is stark. Novartis is doubling down, not diversifying. The company has signed multiple deals for "undruggable cancer targets" — at least three separate transactions with $105M TDVs in June 2026 alone — suggesting a deliberate campaign to build optionality across emerging target classes. Meanwhile, the ADC platform deals on July 8, 2026 represent $2.6B in combined total deal value at the preclinical and discovery stage. That is a massive bet on next-generation conjugation chemistry.

The ANGPTL3 RNA deal ($160M upfront, Phase 2) is the outlier: a more mature asset with a larger upfront commitment, signaling that Novartis will pay for clinical de-risking in cardiometabolic — but only selectively. For benchmarking context on how these mega-deals compare, see the mega-deal benchmarks on Ambrosia.

Deal Type Preferences

Novartis's preferred deal structures across this 56-deal period are acquisitions, collaborations, options, and licenses. The mix tells a clear story: this is a buyer that wants control without committing capital upfront.

The average upfront ratio of 21.8% of total deal value is unambiguously buyer-friendly. For context, the industry median for oncology licensing deals has hovered between 25% and 35% over the past two years. At 21.8%, Novartis is consistently structuring deals where 78% of the value sits in milestones — clinical, regulatory, and commercial. If you are a biotech founder looking at a Novartis term sheet, understand that the majority of the economics you are being offered are contingent on events you may not control post-deal.

The prevalence of option deals and collaborations — particularly for discovery-stage assets — reinforces this posture. Novartis is buying the right to decide later. The option structures give them data readouts before they commit to full licensing economics. The collaboration structures let them co-fund early work while retaining walk-away rights. This is textbook risk mitigation by a company that has been burned by late-stage pipeline failures and is now engineering its deal portfolio to defer binary risk.

Use the Deal Calculator to benchmark whether a 21.8% upfront ratio is competitive for your specific asset stage and therapeutic area.

Strategic Pattern

Three strategic theses emerge from Novartis's deal activity:

• Thesis 1: Own the ADC value chain. The July 2026 ADC platform deals — an NMT inhibitor-based ADC platform ($1.1B TDV) and an ADC payload platform ($1.5B TDV) — are not asset deals. They are infrastructure plays. Novartis is building internal capability to generate proprietary ADCs rather than licensing individual conjugates. This mirrors what Pfizer attempted with Seagen but through a platform-licensing model rather than a $43B acquisition. The economics are radically different: Novartis is spending milestone-weighted dollars, not balance sheet cash, to build comparable capability.
• Thesis 2: Crack the undruggable oncology problem at scale. At least three separate deals targeting "undruggable cancer targets" in June 2026, plus a $1.9B multi-target oncology discovery collaboration and a $1.4B molecular glue program, indicate that Novartis is running a portfolio approach to target classes that have historically defeated pharma — think KRAS beyond G12C, transcription factors, protein-protein interactions. The molecular glue deal at $40M upfront against $1.4B TDV is a 2.9% upfront ratio. That is an extraordinarily back-loaded structure, even by discovery-stage standards.
• Thesis 3: Selective RNA and AI bets outside oncology. The ANGPTL3 RNA deal and the AI-driven protein therapeutics collaboration are strategic hedges. Novartis is not going all-in on these modalities the way Lilly has with RNA or Recursion has with AI. Instead, it is taking measured positions — paying for Phase 2 data in RNA and funding a discovery-stage AI collaboration — to maintain optionality without overcommitting capital. This is a secondary strategy, not a primary one.

The throughline is platform acquisition with milestone protection. Novartis is not buying Phase 3 assets and paying 40% upfronts. It is buying discovery and preclinical platforms, structuring deals at sub-25% upfront ratios, and building long-duration optionality across modalities it believes will define the next decade of oncology.

What This Means If You're Pitching to Novartis

If you are a biotech approaching Novartis for a deal in 2026, here is what the data tells you:

• Lead with platform, not asset. Novartis's recent deal flow overwhelmingly favors platform technologies — ADC systems, molecular glues, undruggable target approaches — over individual clinical-stage molecules. If you have a single asset, you are competing against platform deals where Novartis gets multiple shots on goal for a comparable TDV. Reframe your pitch around the breadth of your technology, not just your lead program.
• Expect a 20–25% upfront ratio. The 21.8% average is not an anomaly; it is policy. Novartis's deal team will push for milestone-heavy structures. If you need more than 25% upfront to fund your operations, come prepared with competitive term sheets from other buyers or demonstrate clinical de-risking that justifies a premium. The ANGPTL3 deal — Phase 2, $160M upfront — shows Novartis will pay more for later-stage assets, but the baseline expectation is back-loaded economics.
• Oncology is the door. If your asset is in oncology — particularly in ADCs, molecular glues, degraders, or novel target classes — you are aligned with Novartis's primary investment thesis. Immunology, neurology, rare disease, and cardiovascular deals are getting done, but at lower frequency and with less apparent strategic urgency. Non-oncology assets need a stronger standalone case.
• Propose option structures. Novartis likes optionality. If you are at the discovery or preclinical stage, proposing an option deal — where Novartis funds development and exercises a licensing option at a predefined milestone — aligns with their revealed preferences. This structure also protects you: if the option is not exercised, you retain your asset.
• Benchmark before you negotiate. With 56 deals in the dataset, there is enough transaction history to model what Novartis will likely offer for your specific asset profile. Use the Partner Matching engine on Ambrosia to score your asset against Novartis's deal history and identify where your terms sit relative to their established range.

See Which Companies Match Your Asset

Novartis is one of 850+ companies scored in the Ambrosia calculator's partner matching engine. Input your therapeutic area, modality, development stage, and target deal economics, and the platform will rank potential partners by fit — including upfront ratio benchmarks, deal structure preferences, and historical TA concentration. If Novartis is your best match, you will know. If it is not, you will know that too.